Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 10/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | SDHB | P21912 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13451114 | 0.83 | PTGS2 (0.48) | PTGS2PTGS1HDAC6SDHBKDM4E | |
| SCHEMBL3152021 | 0.83 | PTGS2 (0.48) | PTGS2PTGS1HDAC6SDHBKDM4E | |
| SCHEMBL1357752 | 0.80 | PTGS2 (0.67) | PTGS2PTGS1HDAC6HSP90AA1 | |
| SCHEMBL22651236 | 0.79 | KDM4E (0.55) | KDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL19243065 | 0.77 | THRB (0.54) | PTGS2HDAC6 | |
| SCHEMBL3166344 | 0.76 | PTGS2 (0.54) | PTGS2PTGS1 | |
| SCHEMBL14002197 | 0.74 | PTGS1 (0.50) | PTGS2PTGS1SDHB | |
| SCHEMBL17306380 | 0.74 | MAPT (0.48) | KDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL3848271 | 0.74 | KMT2A (0.53) | KDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL3161223 | 0.73 | PTGS2 (0.65) | PTGS2PTGS1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1546107-B1 | COX-2 INHIBITING PYRIDINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2010-03-31 | — | — | EP | disclosed |